Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

• Published in: Diabetes, obesity & metabolism Vol. 13; no. 2; pp. 185 - 188
• Main Authors: Lindblad, U., Lindberg, G., Månsson, N.-O., Ranstam, J., Tyrberg, M., Jansson, S., Lindwall, K., Svärdh, M., Kindmalm, L., Melander, A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.02.2011; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Clinical Medicine; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - prevention & control; Endocrinology and Diabetes; Endokrinologi och diabetes; Fasting; Female; Humans; IFG; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; Placebos; Prediabetic State - drug therapy; prevention; Primary care; randomized trial; Retinopathy; Risk Reduction Behavior; Sulfonylurea Compounds - therapeutic use; sulphonylurea; type 2; type 2 diabetes
• ISSN: 1462-8902; 1463-1326; 1463-1326
• DOI: 10.1111/j.1463-1326.2010.01331.x

The Nepi ANtidiabetes StudY (NANSY) is a 5‐year randomized, double‐blind, placebo‐controlled trial in Swedish primary care, examining whether the development of type 2 diabetes (T2D) and retinopathy (separately reported) would be delayed in 40‐ to 70‐year‐old subjects with impaired fasting glucose (IFG) who, in addition to lifestyle changes, were treated with either placebo or low‐dosage sulphonylurea (SU) (1‐mg glimepiride; Amaryl®). Of 274 subjects (163 men, 111 women), 138 were allocated to placebo (46.0% men, 56.8% women) and 136 to glimepiride (54.0% men, 43.2% women). The primary endpoint was conversion to diabetes. Average follow‐up time was 3.71 years; 96 subjects converted to diabetes, 55 allocated to placebo and 41 to glimepiride (absolute difference 9.8%; p = 0.072). In conclusion, the study failed to support the notion that low‐dose SU added to lifestyle changes in IFG subjects would help to delay the conversion to diabetes.